scholarly journals Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4

Cells ◽  
2019 ◽  
Vol 8 (5) ◽  
pp. 416
Author(s):  
Nadia Marascio ◽  
Maria Mazzitelli ◽  
Grazia Pavia ◽  
Aida Giancotti ◽  
Giorgio Settimo Barreca ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Pediatric Patients ◽  
Real Life ◽  
Fixed Dose ◽  
Genotype 4 ◽  
Direct Acting Antiviral ◽  
Life Data ◽  
Real Life Data ◽  
Dose Combination ◽  
Direct Acting

Direct-acting antiviral drugs to cure infections with Hepatitis C virus (HCV) achieve a sustained virological response (SVR) in more than 90% of adult patients. At present, clinical trials are ongoing and real-life data are still limited in children. Herein, we report two cases of pediatric patients treated with fixed-dose combination of sofosbuvir/ledipasvir, already approved to treat HCV4 genotype. Both young girls achieved SVR even though HCV4 isolates carried L28M and M31L NS5A resistance-associated substitutions (RASs). Therefore, possible effects of these RASs merit further study, especially in children.

scholarly journals Efficiency and safety of direct-acting antiviral in cirrhotic hepatitis C infection patients: Real-life data from Turkey

2019 ◽  
Vol 30 (Supp1) ◽  
pp. 106-107
Author(s):  
Yesim Tasova ◽  
◽  
Tansu Yamazhan ◽  
Saban Esen ◽  
Nefise Cuvalci Oztoprak ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Real Life ◽  
Hepatitis C Infection ◽  
Direct Acting Antiviral ◽  
Life Data ◽  
Real Life Data ◽  
Direct Acting

scholarly journals Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C: Real-life Data

2021 ◽  
Vol 27 (2) ◽  
pp. 42-48
Author(s):  
Ayhan Balkan ◽  
Yasemin Balkan ◽  
Abdullah Emre Yıldırım ◽  
Buğra Tolga Konduk ◽  
Sezgin Barutçu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Agents ◽  
Real Life ◽  
Direct Acting Antiviral ◽  
Life Data ◽  
Real Life Data ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

HCV resistance-associated substitutions following direct-acting antiviral therapy failure – Real-life data from Poland

2021 ◽  
pp. 104949
Author(s):  
Miłosz Parczewski ◽  
Ewa Janczewska ◽  
Arkadiusz Pisula ◽  
Dorota Dybowska ◽  
Władysław Łojewski ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Real Life ◽  
Therapy Failure ◽  
Direct Acting Antiviral ◽  
Life Data ◽  
Real Life Data ◽  
Direct Acting

scholarly journals Grazoprevir/elbasvir combination therapy for HCV infection

2016 ◽  
Vol 10 (1) ◽  
pp. 155-167 ◽  
Author(s):  
Anaïs Vallet-Pichard ◽  
Stanislas Pol
Keyword(s):  
Antiviral Agents ◽  
Real Life ◽  
Added Value ◽  
Fixed Dose ◽  
Duration Of Treatment ◽  
Replication Complex ◽  
Direct Acting Antiviral ◽  
Dose Combination ◽  
Direct Acting ◽  
Second Wave

Interferon-free regimens combine different second-wave direct-acting antiviral agents (DAAs), which target the main viral proteins involved in the replication cycle of hepatitis C virus (HCV): NS3/4A protease inhibitors (simeprevir or paritaprevir boosted by ritonavir), NS5B nucleos(t)idic (sofosbuvir) and nonnucleos(t)idic (dasabuvir) polymerase inhibitors, NS5A replication complex inhibitors (daclatasvir, ledipasvir, elbasvir, velpatasvir). Combinations of two or three DAAs, given for 8–24 weeks reach sustained virology response (SVR) rates greater than 90% with good tolerance. SVR rates and safety are similar in clinical trials and in real life, usually higher than 95% in the per-protocol analysis. Next-generation DAAs are now expected. To be competitive, these new combinations need to prove their added value regarding the pill burden, the reduced duration of treatment, the drug–drug interaction profile and safety. Zepatier is a fixed-dose combination product coformulating MK-5172 [grazoprevir (GZR), 100 mg QD] and MK-8742 [elbasvir or (EBR) 50 mg QD]: it combines highly potent inhibitors of the HCV NS3/4A protease and NS5A replication complex, respectively. This review provides a summary of the main evidence available for the use of GZR/EBR and highlights the strength of this combination.

scholarly journals REAL-LIFE DATA ON IMMUNE RECONSTITUTION AFTER ALLOGENIC STEM CELL TRANSPLANTATION: AN OBSERVATIONAL STUDY IN PEDIATRIC PATIENTS

2020 ◽  
Author(s):  
Aline Risson Belinovski ◽  
Polliany Dorini Pelegrina ◽  
Alberto Cardoso Martins Lima ◽  
Gisele Loth ◽  
Adriana Mello Rodrigues ◽  
...  
Keyword(s):  
Stem Cell ◽  
Observational Study ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Immune Reconstitution ◽  
Pediatric Patients ◽  
Real Life ◽  
Allogenic Stem Cell Transplantation ◽  
Life Data ◽  
Real Life Data
Sign in / Sign up

Export Citation Format

Share Document